I came across this study and the results looked very promising in comparison to standard of care alone for GBM. However, the sample size is very small and not statistically significant. With that said, I still think these results are hard to ignore. Especially since only 3 of 20 patients used this combination and the minimum survival time of the 3 was 28 months. (this individual also had dosage reduced because of grade 2 fatigue so there may be some dosage dependance)
Results: The median survival time of the 20 patients was 13.7 months (range: 2.2 to 37 months). Surprisingly,
the 3 patients who received sirolimus and HCQ as an add-on treatment survived for a longer period of time (median
34 months). Transient grade 3 myelotoxicity and grade 2 fatigues were rapidly resolved by treatment interruption or
These patients were much older so would we interesting to see how this therapy would work in younger patients with stronger immune systems.
From Kwan-Hwa Chi, MD in an email to me: " this regimen works better in mesenchymal type of GBM, the worst prognosis one and multiple recurrent case."
See the below link to investigate
Sirolimus and Hydroxychloroquine as an Add-On to Standard Therapy for Glioblastoma Multiforme: Case Report